3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
Systematic (IUPAC) name
(RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone
Clinical data
Legal status
  • UK: Class A
Routes oral, insufflation, Vaporization, IV, rectal, sublingual
Pharmacokinetic data
Metabolism Hepatic
Excretion Primarily Urine (Renal)
Identifiers
CAS number
ATC code ?
PubChem
Chemical data
Formula C14H17NO3 
Mol. mass 247.28 g/mol

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.[1] It shares a similar chemical structure with α-PPP and MDPV.[2][3][4]

Metabolism

MDPPP appears to have a similar metabolic fate as MDPV.[4]

See also

References

  1. ^ Springer, D.; Fritschi, G.; Maurer, H. H. (2003). "Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography–mass spectrometry". Journal of Chromatography B 793 (2): 377.  
  2. ^ Maurer, HH; Kraemer, T; Springer, D; Staack, RF (2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic drug monitoring 26 (2): 127–31.  
  3. ^ Staack, RF; Maurer, HH (2005). "Metabolism of designer drugs of abuse". Current drug metabolism 6 (3): 259–74.  
  4. ^ a b Springer, D; Staack, RF; Paul, LD; Kraemer, T; Maurer, HH (2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica 35 (3): 227–37.